Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Feb 27, 2023; 15(2): 142-162
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.142
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.142
Figure 2 Multidisciplinary teams process for Borderline resectable pancreatic cancer.
BRPC: Borderline resectable pancreatic cancer; NAT: neoadjuvant therapy; (+): No progression or downstaging of disease and no serious adverse effects; (-): Poor response to treatment, disease progression or occurrence of serious adverse effects; MDTs: Multidisciplinary teams.
- Citation: Wu HY, Li JW, Li JZ, Zhai QL, Ye JY, Zheng SY, Fang K. Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress. World J Gastrointest Surg 2023; 15(2): 142-162
- URL: https://www.wjgnet.com/1948-9366/full/v15/i2/142.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i2.142